Announced Mon, 6 Jul · 17:20 IST
Routine compliance certificate for share dematerialization filed
Compliance View source PDF
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+14.2%1-day move
₹20.71
prior close
₹20.32
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————+14.2+11.1+17.7+6.1+3.4+2.5————
Up moveDown movePending
AI summary
Beryl Drugs Ltd has filed a compliance certificate under SEBI Regulation 74(5) for the quarter ended 30 June 2026. The company's registrar, Adroit Corporate Services, has confirmed that all securities received from depository participants for dematerialization during the quarter were processed, and physical certificates were cancelled and replaced with electronic holdings within the required 15-day timeline. This is a standard quarterly compliance filing with no business or financial impact.
Likely market impact
No impact on shareholders or stock. This is a routine regulatory compliance filing with no material information.